1. Volume 373, Issue 9668, Pages 1009-1015 (March 2009)
Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials 
Hiddo J Lambers Heerspink, PharmD, Toshiharu Ninomiya, MD, Sophia Zoungas, MD, Prof Dick de Zeeuw, MD, Prof Diederick E Grobbee, MD, Meg J Jardine, MD, Martin Gallagher, MD, Matthew A Roberts, MD, Prof Alan Cass, MD, Prof Bruce Neal, MD, Dr Vlado Perkovic, MD 
The Lancet 
Volume 373, Issue 9668, Pages (March 2009)
DOI: /S (09)
Copyright © 2009 Elsevier Ltd Terms and Conditions

2. Figure 1 Identification process for eligible studies
*Searches on
The Lancet  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

3. Figure 2
Risk of cardiovascular events for blood pressure lowering treatment versus control regimens
DBP=diastolic blood pressure. SBP=systolic blood pressure. NA=not applicable. The overall mean difference in systolic and diastolic blood pressure in the active treatment group compared with the control group is also shown. Negative values indicate lower mean follow-up blood pressure in the active treatment group.
The Lancet  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

4. Figure 3
Subgroup analyses for the effects of blood pressure lowering agents on cardiovascular events
ACE=angiotensin-converting enzyme. ARB=angiotensin-receptor blocker.
The Lancet  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

5. Figure 4
Risk of all-cause mortality and cardiovascular mortality for blood pressure lowering treatment versus control regimens
NR=not reported.
The Lancet  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions